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Thirty cases of hemorrhagic fever with renal syndrome 
(HFRS) due to Puumala virus (PUUV), Saaremaa virus 
(SAAV), and Dobrava virus infection were conﬁ  rmed in Es-
tonia. Except for the levels of serum creatinine, no remark-
able differences were found in the clinical course of HFRS 
caused by PUUV and SAAV.
H
emorrhagic fever with renal syndrome (HFRS) is an 
endemic zoonosis in Eurasia. In Europe, HFRS is 
caused by 3 hantaviruses: Puumala virus (PUUV), car-
ried by the bank vole (Myodes glareolus); Dobrava virus 
(DOBV), carried by the yellow-necked mouse (Apodemus 
ﬂ  avicollis); and Saaremaa virus (SAAV), carried by the 
striped ﬁ  eld mouse (A. agrarius) (1).
In Estonia, PUUV and SAAV were found in wild 
rodents. High prevalence of human antibodies has been 
detected against SAAV (23%) on Saaremaa Island and 
against PUUV (18%) in central Estonia (2,3). In contrast 
to Slovenia, Croatia, and Bosnia-Herzegovina, where a 
milder HFRS caused by PUUV and a more severe form 
caused by DOBV have been reported (4,5), no severe forms 
of HFRS have been observed in Estonia thus far. Our ﬁ  rst 
report of HFRS in Estonia included cases caused by PUUV 
and SAAV (6). (At that time, SAAV was mistakenly des-
ignated DOBV; therefore, DOBV and SAAV infections 
could not be distinguished.)
No fatal cases have been reported on Saaremaa Island, 
where 23% of the population has antibodies against SAAV; 
this ﬁ  nding strongly suggests that SAAV causes a milder 
form of HFRS. To validate this hypothesis, we analyzed 
clinical data and laboratory ﬁ  ndings in Estonian HFRS pa-
tients infected by different hantaviruses.
The Study
During 1999–2004, serum samples from 321 patients 
with suspected HFRS were analyzed by using ELISA. Of 
these, 30 were conﬁ  rmed for hantavirus infection by the 
Department of Virology, National Institute for Health De-
velopment (Tallinn). Blood samples were collected from 
patients during the acute (at admission to a hospital) and 
convalescent phases (Table 1). The acute-phase serum 
samples were tested by immunoglobulin (Ig) M and IgG 
ELISA as described (7,8). Convalescent-phase serum 
samples were collected from 25 patients, and the causative 
hantavirus was typed by focus reduction neutralization test 
(FRNT) as described earlier (7). We found that 21 patients 
were infected by PUUV, 3 by SAAV, and 1 by DOBV (at 
least a 4-fold higher endpoint titer).
Complete clinical documentation was available for 25 
patients, and their case records were reviewed. One patient 
with PUUV infection, a 1-year-old child, was excluded 
from our study.
The most common clinical symptoms were acute onset 
of disease, fever, and back pain (Table 2). Impaired renal 
function was also noted in almost all patients. Proteinuria 
and microscopic hematuria were reported for all PUUV- 
and SAAV-infected patients, but hematuria was not found 
in the DOBV-infected patient. Oliguria (<400 mL/24 h) 
was noted for 55% of the PUUV patients and all SAAV 
patients; subsequent polyuria (>2,500 mL/24 h) was noted 
for 45% of the PUUV-infected patients and in 67% of the 
SAAV patients. Mild oliguria (380 mL/24 h) and polyuria 
(5,000 mL/24 h) also developed in the patient with DOBV 
infection. One patient with PUUV infection and 1 with 
SAAV infection required hemodialysis because of symp-
toms of uremia. An increased level of serum creatinine was 
found in all patients with PUUV and SAAV infections. The 
mean level of serum creatinine was signiﬁ  cantly higher in 
the SAAV patients (p = 0.043).
Other common abnormalities in laboratory ﬁ  ndings 
were the elevated levels of C-reactive protein, serum urea, 
and transaminases. We observed normal mean levels of 
platelets; however, thrombocytopenia was found in 57.1% 
of the PUUV-infected patients and only in 33% of the 
SAAV-infected patients.
In summary, no remarkable differences in the clinical 
course of HFRS caused by PUUV and SAAV were found. 
The comparison between the 3 groups was difﬁ  cult be-
cause of the small number of patients infected by SAAV 
and DOBV. The only patient with DOBV infection demon-
strated a mild clinical course of disease.
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Conclusions
Because at least 2 hantaviruses, PUUV and SAAV, 
circulate in Estonia, our main aim was to describe the 
clinical courses of HFRS caused by different hantaviruses. 
We found that HFRS cases caused by PUUV, SAAV, and 
DOBV all occurred in Estonia. Approximately 75% of the 
Estonian patients were infected with PUUV, a ﬁ  nding that 
agrees with the more frequent detection of hantavirus anti-
gen in M. glareolus in mainland Estonia. DOBV antibodies 
have been detected in HFRS patients (the present study) 
and in blood donors (9), but the virus has thus far not been 
detected in rodents captured in Estonia.
Hallmarks of HFRS, such as blurred vision and hemor-
rhages, were not frequent among the patients in our study. 
Although acute transient myopia was observed in 25% 
of PUUV-infected patients, the differences between the 
groups were not statistically signiﬁ  cant. In Fennoscandia, 
where only PUUV infections have been reported, visual 
dysfunction has been reported for 31%–36% of the pa-
tients (10,11). In Slovenia, 83% of PUUV-infected patients 
and 42% of DOBV-infected patients reported blurred vi-
sion (4). The reason for different prevalence rates of this 
symptom between countries is unclear, but the type of 
causative hantavirus or lack of a diagnosis of visual dis-
turbance might play a role. Hemorrhagic manifestations 
were found in 3 patients (2 PUUV and 1 SAAV), but no 
statistically signiﬁ  cant differences were found between the 
groups. The patient with a DOBV infection did not show 
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Table 1. Hantavirus-specific antibodies in 30 HFRS patients in Estonia as determined by ELISA and FRNT* 
 ELISA FRNT of convalescent-phase serum
Patient
no.
Time after 
onset, d PUUV IgM/IgG SAAV IgM/IgG
Time after 
onset PUUV SAAV DOBV SEOV
681 13 1.095/0.556† 0.075/0 5 mo 640‡4 0 < 4 0< 4 0
715 12 1.147/0.258 0.052/0.045 21 d 640 <40 <40 <40
716 17 1.072/0.383 0.028/0 1 mo 2,560 <40 <40 <40
718 7 1.079/0.142 0/0.019 1 mo 2,560 <40 <40 <40
728 24 0.602/0.727 0.039/0.145 9 mo 640 <40 <40 <40
731 8 1.43/0.309 0/0.102 24 d 2,560 <40 <40 <40
761 9 1.048/0.213 0.034/0.138 ND ND ND ND ND
763 9 1.309/0.631 0.031/0.088 ND ND ND ND ND
766 15 1.340/0.586 0.036/0.043 7 mo 640 <40 <40 <40
767 16 1.840/0.627 0.040/0.034 12 mo 640 <40 <40 <40
770 13 0.995/0.127 0.231/0.031 5 mo 160 <40 <40 <40
772 6 0.331/0.044 0.137/0.021 11 mo 160 <40 <40 <40
774 4 1.361/0.863 0.103/0.088 11 mo 160 <40 40 <40
800 8 1.151/0.152 0/0.099 ND ND ND ND ND
812 9 1.144/0.244 0.026/0.046 9 mo 640 <40 <40 <40
813 7 1.058/0.089 0.082/0.06 2 mo 640 <40 <40 <40
840 8 0.724/0.038 0.083/0.055 9 mo 640 <40 <40 <40
841 8 0.704/0.142 0.073/0.013 20 d 2,560 160 160 <40
855 24 0.791/0.152 0.632/0.090 1 mo 640 40 40 <40
857 5 1.133/0.043 1.053/0.067 ND ND ND ND ND
861 23 1.051/0.184 0.559/0.035 1.5 mo 640 <40 <40 <40
895 5 0.957/0.135 ND/0.011 1 mo 2,560 <40 <40 <40
899 13 0.797/0.120 ND/0.005 1.5 mo 160 <40 <40 <40
927 11 0.833/0.279 ND/0.004 1.5 mo 640 <40 40 <40
933 5 0.569/0.464 ND/0.116 18 mo 160 <40 40 <40
691 6 0.355/0.047 1.014/0.081 4 mo <40 160 40 <40
769 10 0.271/0 0.218/0.254 20 d <40 2,560 640 <40
801 14 0/0.038 0.394/1.548 1.5 mo <40 640 160 <40
849 4 0.011/0 0.599/0.133 ND ND ND ND ND
795 12 0.144/0 0.442/362 11 mo <40 160 640 <40
*HFRS, hemorrhagic fever with renal syndrome; FRNT, focus reduction neutralization test; PUUV, Puumala virus; SAAV, Saaremaa virus; Ig, 
immunoglobulin; DOBV, Dobrava virus; SEOV, Seoul virus; ND, not done. Numbers in boldface indicated positive results in ELISA and at least 4-fold 
higher titer in FRNT. The cut-off value for ELISA was set at OD = 0.100. 
†Mean optical density (OD) for duplicate samples. 
‡Reciprocal endpoint titer at an 80% reduction. Hemorrhagic Fever with Renal Syndrome Cases, Estonia
any signs of hemorrhages. Normal levels of mean plate-
let counts were found in all groups of our HFRS patients, 
although in 57% and 33% of PUUV- and SAAV-infected 
patients, respectively, a mild thrombocytopenia was found. 
Slovenian DOBV-infected patients had signiﬁ  cantly lower 
platelet counts than PUUV-infected patients (4). Thrombo-
cytopenia was also observed for 75% and 52% of patients 
in Finland and Sweden, respectively (10,11). 
Gastrointestinal symptoms are common in hantavirus 
infections. We did not, however, ﬁ  nd signiﬁ  cant differ-
ences between the PUUV- and SAAV-infected patients, 
although diarrhea and abdominal pains were more com-
mon in SAAV- than PUUV-infected patients. In our study, 
transient impairment of renal function was noted in all 
patients, together with elevated levels of serum urea and 
creatinine, ﬁ  ndings in line with those from previous stud-
ies in other countries. Our study demonstrated that HFRS 
symptoms were not generally distinguishable between the 
PUUV- and SAAV-infected patient groups. Only the level 
of serum creatinine was signiﬁ  cantly higher in the SAAV-
infected patients.
Two forms of HFRS have been reported from the Bal-
kans, a mild form with mortality rates up to 0.1% caused 
by PUUV, and a severe form with mortality rates >10% 
caused by DOBV. On the other hand, in Estonia and other 
countries such as Germany, Denmark, Slovakia, Latvia, 
and Lithuania, where SAAV (or DOBV-Aa, as SAAV is 
occasionally designated) circulates, no fatal cases have 
been reported. 
The symptoms caused by different hantaviruses range 
from subclinical or mild to very severe. Knowledge con-
cerning all the parameters involved in the disease severity 
is still lacking. Besides the genotype of the causative hanta-
virus, human HLA-B8, -DR3, and -DQ2 alleles may be as-
sociated with more or less serious symptoms in HFRS (12). 
Our study included only hospitalized HFRS patients. More 
attention should be paid to outpatients referred to family 
doctors, infectious disease specialists, and nephrologists.
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Table 2. Frequency of clinical symptoms and laboratory findings in 24 HFRS patients, Estonia* 
No. patients (%) 
Findings PUUV, n = 20 (%)  SAAV, n = 3 (%)  DOBV, n = 1 
Signs and symptoms 
  Fever  20 (100)  3 (100)  1
  Headache  8 (40)  3 (100)  0
  Abdominal pain  11 (55)  3 (100)  1
  Back pain  16 (80)  2 (67)  1
  Nausea/vomiting  11 (55)  2 (67)  1
  Hemorrhage  2 (10)  1 (33)  0
 Visual  impairment  5  (25)  0 0
  Diarrhea  3 (15)  2 (67)  1
  Oliguria (<400 mL/d)  11 (55)  3 (100)  1
  Polyuria (>2,500 mL/d)  9 (45)  2 (67)  1
  Hematuria (microscopic)  20 (100)  3 (100)  0
  Hemodialysis  1 (5)  1 (33)  0
Laboratory findings  Mean value (% patients with abnormal findings), range 
  Leukocyte count, 4–10 × 10
9/L 11 (58), 5.7–24.4  9 (33), 8.1–11.3  5
  Thrombocyte count, 100–400 × 10
9/L 120 (57), 12.6–350  126 (33), 90–163  174
  C-reactive protein <10 mg/L  84 (94), 9.7–229.8  69 (100), 52–95  168
  Serum urea, 2.8–8.3 mmol/L  23 (94), 5.0–87.0  31 (100), 20.1–42.5  ND
  Serum creatinine, 35–115 μmol/L  303 (100), 120–1,124  606 (100)†, 489–796  98
  AST <26 U/L  74 (100), 28–205  56 (100), 39–77  122
  ALT <35 U/L  62 (88), 20–233  71 (100), 41–123  ND
  Proteinuria (g/L)  3 (95), 0.25–11.8  7 (100), 1.06–17.8  1
*HFRS, hemorrhagic fever with renal syndrome; PUUV, Puumala virus; SAAV, Saaremaa virus; DOBV, Dobrava virus; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase. 
†Statistically significant result, p<0.05. DISPATCHES
  2.   Golovljova I, Sjolander KB, Lindegren G, Vene S, Vasilenko V, 
Plyusnin A, et al. Hantaviruses in Estonia. J Med Virol. 2002;68: 
589–98.
  3.   Nemirov K, Vapalahti O, Lundkvist A, Vasilenko V, Golovljova I, 
Plyusnina A, et al. Isolation and characterization of Dobrava han-
tavirus carried by the striped ﬁ  eld mouse (Apodemus agrarius) in 
Estonia. J Gen Virol. 1999;80:371–9.
  4.   Avsic-Zupanc T, Petrovec M, Furlan P, Kaps R, Elgh F, Lundkvist 
A. Hemorrhagic fever with renal syndrome in the Dolenjska region 
of Slovenia—a 10-year survey. Clin Infect Dis. 1999;28:860–5.
  5.   Hukic M, Tulumovic D, Calkic L. The renal failure and capillary 
leak during the acute stage of (Dobrava) DOB and PUU (Puumala) 
infection [in Bosnian]. Med Arh. 2005;59:227–30.
  6.   Golovljova I, Vasilenko V, Prukk T, Brus Sjolander K, Plyusnin A, 
Lundkvist A. Puumala and Dobrava hantaviruses causing hemor-
rhagic fever with renal syndrome in Estonia. Eur J Clin Microbiol 
Infect Dis. 2000;19:968–9.
  7.   Lundkvist A, Hukic M, Horling J, Gilljam M, Nichol S, Niklas-
son B. Puumala and Dobrava viruses cause hemorrhagic fever with 
renal syndrome in Bosnia-Herzegovina: evidence of highly cross-
neutralizing antibody responses in early patient sera. J Med Virol. 
1997;53:51–9.
  8.   Sjolander KB, Elgh F, Kallio-Kokko H, Vapalahti O, Hagglund M, 
Palmcrantz V, et al. Evaluation of serological methods for diagnosis 
of Puumala hantavirus infection (nephropathia epidemica). J Clin 
Microbiol. 1997;35:3264–8.
  9.   Sjolander KB, Golovljova I, Vasilenko V, Plyusnin A, Lundkvist 
A. Serological divergence of Dobrava and Saaremaa hantaviruses: 
evidence for two distinct serotypes. Epidemiol Infect. 2002;128: 
99–103.
10.   Mustonen J, Brummer-Korvenkontio M, Hedman K, Pasternack A, 
Pietila K, Vaheri A. Nephropathia epidemica in Finland: a retrospec-
tive study of 126 cases. Scand J Infect Dis. 1994;26:7–13.
11.   Settergren B, Juto P, Trollfors B, Wadell G, Norrby SR. Clinical 
characteristics of nephropathia epidemica in Sweden: prospective 
study of 74 cases. Rev Infect Dis. 1989;11:921–7.
12.   Mustonen J, Partanen J, Kanerva M, Pietila K, Vapalahti O, Paster-
nack A, et al. Genetic susceptibility to severe course of nephropathia 
epidemica caused by Puumala hantavirus. Kidney Int. 1996;49: 
217–21.
Address for correspondence: Åke Lundkvist, Swedish Institute for 
Infectious Disease Control, SE-171 82 Solna, Sweden; email: ake.
lundkvist@smi.ki.se
1776  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 11, November 2007
Search 
past Issues